Agilent Announces Deals in South Korea for Clinical Assay Development, Neurometabolomic Research | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies separately announced on Thursday a collaboration with Samsung Medical Center and the creation of a new center for neurometabolomics in South Korea.

Under the terms of the deal with Samsung, the Department of Laboratory Medicine & Genetics Research in Seoul, South Korea — part of the Center for Future Medicine at Samsung Medical Center — will use bio-analytical instruments from Agilent for the analysis of clinical samples and to develop novel clinical assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.